Ascentage Pharma Director Lippman Files Amended Ownership Report
ASCENTAGE PHARMA GROUP INTERNATIONAL
Subscribe to track AAPG
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Ascentage Pharma Director Files Amended Ownership Report
Company: ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Form: 3/A (Amendment) | Filed: 2026-03-23 Significance: Low
Insider: Marc E. Lippman Title: Director | Relationship: Director
Filing Details: • Type: Correction to Initial Statement of Ownership • Common Shares Held: 21,174 • Derivatives Held: 17,965 Options ($8.14 strike) + 27,965 RSUs • Reason: Correction of inadvertently incorrect reporting of Options/Vesting in original submission.
Key Insight: This is a clerical amendment to correct the count of derivative securities (Options and RSUs) held by the director. It does not represent a new open market transaction.
Market Context: Ascentage is a $16.35B market cap pharmaceutical company. The director's holdings represent <0.02% of shares outstanding.
Comprehensive Analysis
SEC Filing Analysis: ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
Executive Summary
- Trading Significance: Low
- Key Takeaway: Director Marc E. Lippman filed a Form 3/A to correct administrative errors regarding the number of Options and RSUs reported in a previous submission.
- Market Impact: Neutral. This is a clerical update establishing baseline ownership, not a trading signal.
Company Information
| Field | Value |
|---|---|
| Company | ASCENTAGE PHARMA GROUP INTERNATIONAL |
| Ticker Symbol | AAPG |
| CIK | 0002023311 |
| Industry | Pharmaceutical Preparations |
Insider Information
| Field | Value |
|---|---|
| Name | Marc E. Lippman |
| CIK | 0001202794 |
| Title/Position | Director |
| Relationship | Director |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 3/A (Initial Statement Amendment) |
| Filing Date | 2026-03-23 |
| Transaction Code | None (Holding Report) |
| Security Type | Ordinary Shares & Derivatives |
| Shares Owned (Direct) | 21,174 |
| Derivative Holdings | 17,965 Options; 27,965 RSUs |
| Ownership Type | Direct |
Financial Impact Assessment
Materiality Context
| Metric | Value |
|---|---|
| Market Cap | $16.35 Billion |
| Shares Outstanding | 373,320,000 |
| Insider Total Equity Interest | ~67,104 shares (including unvested derivatives) |
| % of Shares Outstanding | ~0.018% |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: For a Large Cap company ($16.35B), the holdings disclosed (~$170k-$500k estimated value depending on spot price) are immaterial to the broader market structure.
- Ownership Concentration: The insider holds a negligible percentage (<0.02%) of the total float.
- Transaction Significance: This filing is purely administrative. Footnote 4 explicitly states: "The number of Share Options and/or vesting were inadvertently incorrectly reported in the original submission."
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: There is no change in sentiment or capital flow. The filing merely ensures compliance with SEC reporting accuracy for existing compensation packages.
Volume & Sentiment
- Expected Volume Impact: None.
- Sentiment Indicator: Neutral.
Additional Context
Transaction Notes
- Derivatives: The director holds options exercisable at $8.14 (converted from HKD) expiring in 2035, and RSUs vesting through 2029.
- Vesting Schedule: Options vest monthly starting Nov 2025; RSUs vest annually through 2029, indicating a long-term incentive structure.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.